anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A monitor remote control method and system thereof using a mobile terminal. The system comprises: a mobile terminal, a monitor terminal and a network terminal. The mobile terminal comprises an instruction setting unit for inputting setting instructions and sending the setting instruction to the network terminal. The network terminal comprises a data and instruction receiving unit for receiving the setting instructions, and a wireless connection unit for building a wireless connection between the mobile terminal and the monitor terminal. The monitor terminal comprises a setting execution unit for receiving and executing the setting instructions sent by a data and instruction sending unit of the network terminal. The system enables medical staffs when away from bedside to know information and parameter conditions of patients in real time and to set the settings of the monitor.
Patients receive 37.5 mg oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
PURPOSE:To obtain a protecting agent for human hair of the head effective in preventing (preventing and treating) alopecia considered as due especially to premature alopecia. CONSTITUTION:The protecting agent for hair of the head is obtained by directly using a fruit body of a mushroom belonging to the genus Flammulina Karst. or its equivalent (e.g. a cultured tissue) or drying the fruit body, then immersing the fruit body in an aqueous solvent for a prescribed time or thermally boiling the fruit body in the solvent, separating and removing solid ingredients according to a suitable separating means and including the aqueous solvent extract as an active ingredient therein. An ingredient derived from the viscera of a cuttlefish or an octopus (e.g. a higher unsaturated fatty acid or its triglyceride or ink) can further be blended in this protecting agent for the hair of the head.
PURPOSE: An oxidative hair colorant is provided to improve coloring uniformity by a mixture of toluene-2,5-diamine and 2,4-diaminophenoxyethanol. CONSTITUTION: An oxidative hair colorant is prepared by mixing a first agent containing toluene-2,5-diamine and 2,4-diaminophenoxyethanol and a second agent containing an oxidant. Arginine is mixed with the first agent. The oxidative hair colorant is alkaline and has a pH concentration of 11.0 or lower. The amount of arginine is 5 mass% or less. The alkalinity of the first agent is 9.0 or lower.
OBJECTIVE: Central odontogenic fibromas (COF) are rare, benign tumors derived from dental mesenchymal tissue that may occur in the maxilla or mandible. This report describes primary and recurrent COF in the mandible of a patient with nevoid basal cell carcinoma syndrome (NBCCS).
STUDY DESIGN: A 36-year-old African American male presented with a COF and its recurrence 17 months later. Tissue pieces were obtained from both occurrences with IRB-approved signed consent. Collected tissue pieces were dissected; one portion was formalin-fixed and paraffin-embedded, and the other was cultured for the isolation of cell populations from the primary (COdF-1) and recurrent (COdF-1a) tumors. Quantification real-time polymerase chain reaction (qRT-PCR), immunohistochemistry, and DNA sequencing were used for gene and protein analysis of the primary tumor and cell populations.
RESULTS: Histopathologic analysis of the tumor showed sparse odontogenic epithelial cords in fibrous connective tissue, and qRT-PCR analysis of tumor and cell populations (COdF-1 and COdF-1a) detected VIM, CK14, CD34, CD99 and ALPL mRNA expression. Protein expression was confirmed by immunohistochemistry. CD34 expression in primary tissues was higher than in tumor cells due to tumor vascularization. DNA sequencing indicated the patient had PTCH1 mutations.
CONCLUSIONS: Histopathology, mRNA, and protein expression indicate the rare occurrence of COF in a patient with mutated PTCH1 gene and NBCCS.
Dandruff and scalp discomfort are common concerns for women and men in Africa. Moreover, women with afro-textured hair are prone to scalp discomfort owing to irregular hair washing, frequent use of oil-based products on their scalp, and harsh chemical treatments. Current literature does not, however, provide data on the pathophysiological mechanisms of these conditions in this population. In this study, we investigated the mechanisms behind scalp discomfort and dandruff in women of African descent before and after hair washing. We conducted the in Durban, South Africa, over a 3-week period with 60 women of African descent aged 20-40 years. The respondents were equally divided into a "dandruff" and a "no dandruff" group, based on clinical grading of adherent dandruff by a dermatologist. Malassezia spp. and bacterial loads were quantified by quantitative polymerase chain reaction. Evaluations of scalp condition and sample collection were performed at five time points during the 3 weeks. Data on discomfort symptoms were collected via a self-assessment questionnaire. We observed that the dandruff severity peaked at the end of the first week after hair washing and plateaued from thereon in both groups. Dandruff was associated with higher Malassezia and bacterial load counts and there was a direct correlation between the Malassezia spp. load and dandruff score. Via self-assessment questionnaire responses submitted by participants, we observed that itching was the most pronounced scalp discomfort, compared with the sensation of tingling and burning at baseline, while an improvement of the scalp symptoms of dandruff and itch was observed in both groups after one hair wash. The study also showed that higher colonization with Malassezia spp. and bacteria is associated with dandruff independently of the time point, confirming a scalp microbiome contribution to the dandruff pathophysiology in the study population. The benefits of washing were, however, not sustained after 1 week and we thus recommend weekly hair washing for long-term management of dandruff and scalp itchiness in this population.
The present invention relates to a method of modifying Angiotensin II subtype 1 (AT 1 ) receptor activity for the treatment of premenstrual syndrome (PMS) and the symptoms associated therewith, and further relates to a method for the treatment of acute or chronic pain mediated by the sympathetic nervous system. The treatment includes the administration of an effective amount of an AT 1  antagonist. AT 1  antagonists are drugs that are capable of blocking AT 1  receptors present within the body throughout the central nervous system including the hypothalamus. By blocking the AT 1  receptor activity, hypothalamic nerve activity, and therefore, sympathetic nerve activity are modulated. Thus, an effective method for treating sympathetically mediated pain is provided, as well as an effective method for treating PMS. The AT 1  antagonist can be used alone or in combination with other drug therapies, for instance, non-steroidal anti-inflammatory drugs, antidepressants, opiod drugs, angiotensin converting enzyme inhibitors, and diuretics.
The dysregulated levels of branched chain amino acids (BCAA) contribute to renal fibrosis in chronic kidney disease (CKD), yet specific analysis of BCAA contents and how they are regulated still remain unclear. It is therefore of great scientific interest to understand BCAA catabolism in CKD and develop a sensitive method for simultaneous determination of individual BCAA and their metabolites branched chain α-ketoacids (BCKA). In this work, the important role of BCAA metabolism that drives renal fibrosis in the process of CKD was first revealed by using transcriptomics. The key target genes controlling BCAA metabolism were then validated, that is, mRNA levels of BCKDHA and BCKDHB, the regulating rate-limiting enzymes during BCAA metabolism were abnormally reduced by quantitative PCR (qPCR), and a similar drop-off trend of protein expression of BCKDH, HIBCH and MCCC2 that are closely related to BCAA metabolism was also confirmed by western blotting. Furthermore, we established a novel strategy that simultaneously determines 6 individual BCAA and BCKA in serum and tissue. The method based on dansylhydrazine derivatization and ultra-high performance liquid chromatography-tandem triple quadrupole mass spectrometry (UHPLC-QQQ-MS) achieved to simultaneously determine the contents of BCAA and BCKA, which is efficient and stable. Compared with normal rats, levels of BCAA including leucine, isoleucine and valine in serum and kidney of CKD rats was decreased, while BCKA including α-ketoisocaproic acid, α-ketomethylvaleric acid and α-ketoisovaleric acid was increased. Together, these findings revealed the abnormality of BCAA metabolism in driving the course of kidney fibrosis and CKD. Our current study sheds new light on changes in BCAA metabolism during CKD, and may facilitate development of drugs to treat CKD and renal fibrosis.
BACKGROUND: Migraine is a multiphasic neurovascular disorder, where headache can be succeeded by postdromal symptoms. However, there are limited research on postdromal symptoms. This study aimed to investigate the proportion of individuals with migraine from a tertiary care unit reporting postdromal symptoms in adherence with the ICHD-3 definition. We also aimed to examine how the means of enquiry might influence the estimated proportions. Additionally, we explored whether any clinical features might affect the likelihood of reporting postdromal symptoms. Finally, we assessed to what extend the postdromal symptoms might impact the disease burden.
METHODS: In a cross-sectional study, we enrolled adult participants diagnosed with migraine who were asked to report their postdromal symptoms (i.e., unprompted reporting). Subsequently, a 16-item list was used to further ascertain the occurrence of postdromal symptoms (i.e., prompted reporting). Clinical characteristics were obtained through a semi-structured interview. Moreover, electronic questionnaires were used to assess the disease burden, i.e., the Six-Item Headache Impact Test (HIT-6), Migraine Disability Assessment (MIDAS), and the World Health Organization Disability Assessment 2.0 (WHODAS 2.0).
RESULTS: Among 631 participants with migraine, a higher proportion experienced at least one postdromal symptom when prompted (n = 509 [80.7%]) compared with unprompted reporting (n = 421 [66.7%], P < 0.001). Furthermore, the total number of postdromal symptoms experienced was greater with prompted than unprompted reporting (medians 3 [IQR 1 - 6] versus 1 [IQR 0 - 2]; P < 0.001). Furthermore, the likelihood of reporting postdromal symptoms increased with the presence of premonitory symptoms and decreased with higher number of monthly migraine days. Weak correlations were identified between the number of postdromal symptoms reported and both HIT-6 (ρ = 0.14; P < 0.001) and WHODAS scores (ρ = 0.15; P < 0.001), whilst no correlation was observed with MIDAS score (ρ = 0.08; P = 0.054).
CONCLUSIONS: Postdromal symptoms are prevalent in individuals with migraine from a tertiary care unit. However, reported estimates warrant cautious interpretation as they depend on the means of enquiry, presence of premonitory symptoms, and frequency of monthly migraine days. Moreover, a weak correlation was identified between the number of postdromal symptoms and both HIT-6 and WHODAS scores, indicating only a marginal influence on the disease burden.
A system and method are disclosed for sharing session information. The system comprises a database system, a first computer system capable of accessing the database system, and a second computer system also capable of accessing the database system. A user accesses a first website hosted by the first computer system, and a session is initialized for the user. A profile object is created for the user and serialized. The serialized profile object is subsequently stored in the database system with a key. The second computer system queries the database system in order to retrieve the serialized profile object matching the key. The second computer deserializes the profile object and restores the session at the second website together with shared session information.
PURPOSE:To obtain a melanogenesis suppressor consisting of an O-glycoside of tetrahydrocopalol and useful for preventing and improving chromatosis and obtain a skin external preparation containing the suppressor. CONSTITUTION:This melanogenesis suppressor consists of an O-glycoside of tetrahydrocopalol expressed by the formula (R is a monosaccharide residue, a disaccharide residue or a trisaccharide residue). The compound of the formula has suppressing action on melanogenesis and suppressing action on pigmentation and the compound is excellent in whitening effect and it has high stability and safety. This skin external preparation is obtained by blending 0.0001-10wt.% of the compound of the formula into a skin external preparation base. Since the resultant skin external preparation is remarkably excellent in whitening effect on skin and useful for improving and treating local chromatosis such as stain, ephelis or blacked skin due to sunburn and systemic chromatosis such as Addison's disease and it has high safety, the skin external preparation can continuously be used for a long period. The preparation can be prepared in a formulation such as ointment, cream, milky lotion, lotion, pack or a bathing agent.
Through this pilot study, the investigators propose to create new intersections between video art and clinical care by photographing and videotaping patients with brain tumors before, during and after pet therapy sessions. This exploratory scholarship has two equally compelling goals. First, the artistic component of the project aims to create compelling slow motion video portraits of patients' willing to share their experiences of what it is like to confront such a grave illness. The goal is to put a human face on disease and share the endurance of the human spirit through art. Second, the scientific component will assess the potential of using facial video portraits as a novel and innovative way to measure Quality of Life (QOL) in lieu of questionnaires in brain tumor patients. In addition, the project will evaluate the effects of pet therapy on the QOL of these patients.
### Pregnancy Category B

There are no adequate and well-controlled studies of ELIQUIS in pregnant women. Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery. ELIQUIS should be used during pregnancy only if the potential benefit outweighs the potential risk to the mother and fetus.

Treatment of pregnant rats, rabbits, and mice after implantation until the end of gestation resulted in fetal exposure to apixaban, but was not associated with increased risk for fetal malformations or toxicity. No maternal or fetal deaths were attributed to bleeding. Increased incidence of maternal bleeding was observed in mice, rats, and rabbits at maternal exposures that were 19, 4, and 1 times, respectively, the human exposure of unbound drug, based on area under plasma-concentration time curve (AUC) comparisons at the maximum recommended human dose (MRHD) of 10 mg (5 mg twice daily).
PURPOSE: It is unclear which triceps tendon repair constructs and techniques produce the strongest biomechanical performance while minimizing the risk of gap formation and repair failure. We aimed to determine associations of construct and technique variables with the biomechanical strength of triceps tendon repairs. PubMed, Embase, Cochrane Library, Web of Science, Scopus, and ClinicalTrials.gov were systematically searched for peer-reviewed studies on biomechanical strength of triceps tendon repairs in human cadavers. 6 articles met the search criteria. Meta-regression was performed on the pooled dataset (123 specimens). Outcomes of interest included gap formation, failure mode, and ultimate failure load. Covariates were fixation type; number of implants; and number of sutures. Stratification by covariates was performed. We found no association between fixation type and ultimate failure load; however, suture anchor fixation was associated with less gap formation compared with transosseous direct repair (β =  - 1.1; 95% confidence interval [CI]:- 2.2, - 0.04). A greater number of implants was associated with smaller gap formation (β = - 0.77; 95% CI: - 1.3, - 0.28) while a greater number of sutures was associated with higher ultimate failure load ( β= 3; 95% CI: 21, 125). In human cadaveric models, the number of sutures used in triceps tendon repairs may be more important than the fixation type or number of implants for overall strength. If using a transosseous direct repair approach to repair triceps tendon tears, surgeons may choose to use more sutures in their repair in order to balance the risk of larger gap formation when compared to indirect repair techniques.
LEVEL OF EVIDENCE: Level III.
Gabapentin tablets USP are an anticonvulsant for oral administration. Gabapentin USP is described as 1-(aminomethyl)cyclohexaneacetic acid. Gabapentin USP is a white to off-white crystalline solid with a pKa1 of 3.7 and a pKa2 of 10.7. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is -1.25. The structural formula of gabapentin USP is:

C9H17NO2 M.W. 171.24

Each gabapentin tablet USP, for oral administration, contains 600 mg or 800 mg of gabapentin USP and contains the following inactive ingredients: lactose monohydrate, microcrystalline cellulose and polyethylene glycol.
PURPOSE:To provide an acetoaminophene preparation suppressed in the change of color and having a high commercial value by containing acetoaminophene and an antacid wherein at least one of the acetoaminophene and the antacid is coated with a coating agent. CONSTITUTION:1 pt.wt. of acetoaminophene, a non-pyrazolone analgestic agent called paracetamol, 0.05-100 pts.wt. of an antacid (e.g. magnesium silicate or synthetic hydrotalcite) and suitable amounts of conventional additives are compounded by a conventional method and subsequently prepared to provide the objective preparation. At least one of the acetoaminophene and the antacid is therein coated with a water-soluble coating agent to provide a solid preparation. The preparation is reduced in the change with the elapse of time has excellent stability, and can be readily prepared rendering themselves mild acetoaminophene for stomachs because the antacid is compounded.
This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will receive 0.075mg gestodene/0.03mg ethinylestradiol (Gynera®, Bayer Schering Pharma AG, Germany) from day 2 of the preceding cycle for 21 days followed by GnRH antagonist COH.
Regression associated antigens (RAAs) are identified in material from neoplastic cells by their immunological reactivity with regression associated antibodies from the serum of patients diagnosed as undergoing regression of a tumor. Regression associated antibodies (RAAbs) are identified by their absence during progression of a neoplastic disease state and by their presence in a diagnosed state of regression. RAAs have been purified and used to monitor the condition of cancer patients. Production of RAAbs and treatments employing those antibodies are described. It is herein disclosed that RAAs are expressed by $i(M. hyorhinis) and are also expressed by expression of provided nucleotide sequences in recombinant host cells, particularly nucleotide sequence for 38 kd and 43 kd RAAs as expressed in $i(E. coli). RAAs and nucleic acids encoding RAAs (or portions thereof) and RAAbs may be used in diagnostic assays and immunotherapy. RAAbs and fragments portion thereof may be used in passive immunization therapy and radioisotope or magnetic resonance scanning.
No recruitment maneuvers. PEEP at 2 cmH2O. During CPB: continuous positive pressure at 2 cmH2O.
AIM: Some studies have reported that body composition profiles affect clinical outcomes of multidisciplinary treatments in several types of cancers; however, a paucity of data exists on the association in neoadjuvant immunotherapy. In the present study, we aimed to investigate the effect of body composition on the clinical outcomes of patients with esophageal squamous cell carcinoma (ESCC) receiving neoadjuvant immunotherapy plus chemotherapy (nICT).
METHODS: Clinicopathological data and computed tomography (CT) images of 85 patients with locally advanced ESCC who underwent esophagectomy after nICT were collected. At diagnosis and before surgery, the CT scan of the third lumbar vertebra was chosen to evaluate the skeletal muscle index (SMI), skeletal muscle radiodensity (SMD), the subcutaneous and the visceral adiposity index. The relationships between body composition and tumor response after nICT and postoperative complications were analyzed.
RESULTS: The clinical stage (Odds Ratio (OR) 0.345, 95% confidence interval (CI) 0.141-0.844, p = 0.020) and change in SMI (∆SMI, OR 1.394, 95% CI 1.061-1.832, p = 0.017) were associated with tumor remission after nICT. Moreover, the multivariate logistic analysis revealed that ∆SMI (OR 0.598, 95% CI 0.433-0.828, p = 0.002) was associated with the incidence of postoperative complications. Patients with ∆SMI <-1 had a higher rate of postoperative complications (56% vs 15%, p < 0.001).
CONCLUSIONS: For ESCC, ∆SMI is associated with the pathological response after nICT and postoperative complications. Further analysis is needed to clarify whether nutritional intervention during neoadjuvant therapy increases SMI and thus improves clinical outcomes.
The aim of this study is to describe the anaesthesia management of two patients undergoing carinal resection under veno-venous extracorporeal membrane oxygenation (VV ECMO). In both cases, anaesthesia was induced and then maintained with inhalational agents during pneumonectomy and mediastinoscopy (respectively). Then the jugular and femoral veins were cannulated and VV ECMO was started after heparinization. One of the patients presented bleeding during surgery, which was treated with low-dose vasopressors (norepinephrine) and transfusion of platelets, fresh frozen plasma, and concentrated red blood cells. During VV ECMO, anaesthesia was maintained with target-controlled infusion of propofol. VV ECMO can be expected to improve surgical conditions in tracheal surgery; however, it is still a novel technique in this context. In selected patients, it would guarantee ventilatory support during carinal resection, but it is essential to carefully plan anaesthesia maintenance and prepare for VV ECMO-related complications. This technique should only be used in tertiary centres with experience in VV ECMO management.
The invention discloses a double-layer hydrogel intestinal tract delivery carrier and application thereof, and belongs to the technical field of carrier delivery. The bilayer hydrogel enteric delivery vehicle consists of the following components: a cross-linked hydrogel matrix, a carrier matrix implanted within the hydrogel matrix, the carrier matrix for encapsulating an active substance to be delivered; the hydrogel matrix is CMCS-PSDs formed by crosslinking carboxyl modified chitosan and oxidized dialdehyde polysaccharide; the carrier matrix is carboxymethyl cellulose. Use of the bilayer hydrogel enteric delivery vehicle in the preparation of a formulation for targeted delivery to the intestine. The invention also discloses a probiotic preparation, which consists of a double-layer hydrogel intestinal canal delivery carrier and probiotics to be delivered, wherein the probiotics are encapsulated in a carrier matrix. The invention also discloses a preparation method of the probiotic preparation. The double-layer hydrogel intestinal tract delivery carrier can protect active substances to smoothly reach intestinal tracts, and has important significance for researching the directional delivery of the active substances.